Kind Pharmaceuticals

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney DiseaseMyelodysplastic Syndromes

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
AND017Phase 2β -Thalassemia
Est. primary completion 2026-12 · NCT06302491 · CT.gov ↗
What to watch
AND017Phase 2Myelodysplastic Syndromes
Est. primary completion 2026-12 · NCT06304103 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
AND017Phase 3Anemia Due to Chronic Kidney Disease
Est. primary completion 2027-02-20 · NCT07494409 · CT.gov ↗
What to watch
March 2027 (1)
AND017Phase 3Anemia Due to Chronic Kidney Disease
Est. primary completion 2027-03-01 · NCT07487727 · CT.gov ↗
What to watch
December 2027 (1)
AND017Phase 2Chemotherapy Induced Anemia
Est. primary completion 2027-12 · NCT06075030 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
AND017Phase 2Cancer-Related Anemia
Est. primary completion 2028-05 · NCT06075043 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.